Date: 2013-08-26
Type of information: Company acquisition
Acquired company: Zymenex (Denmark)
Acquiring company: Chiesi (Italy)
Amount:
Terms: * On August 26, 2013, Chiesi Group, a leading European pharmaceutical company, has announced that it has signed, through its UK affiliate, Chiesi Ltd., a definitive agreement with Sunstone Capital to acquire Zymenex Holding A/S and its related group of companies, a biopharmaceutical group focused on research and development of innovative biologic therapeutics for the treatment of rare and life threatening genetic diseases. Terms of the transaction were not disclosed.
Details: The acquisition of Zymenex includes Lamazym™ (rhLAMAN), a phase III recombinant enzyme indicated for use to treat patients suffering from alpha-Mannosidosis, as well as other early stage compounds. Zymenex R&D capabilities will establish a research and development position for Chiesi in the recombinant biologics market for rare diseases and provide a new channel for continued global growth. Chiesi will leverage its expertise in commercializing innovative pharmaceutical solutions to bring the treatment to all the worldwide patients suffering from alpha-mannosidosis. Chiesi expects to gradually integrate Zymenex into its R&D structure and retain the Zymenex and Lamazym™ brands.
Related: Rare diseases
